SELECTED FINANCIAL INFORMATION 3 CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As of December 31, In thousands of euros 2016 2017 Cash and cash equivalents 53,982 55,448 Short-term investments — — Total assets 59,231 62,212 Total shareholders’ equity 53,340 54,996 Total non-current liabilities 2,995 3,121 Total current liabilities 2,895 4,095 Total liabilities 5,890 7,216 Total liabilities and shareholders’ equity 59,231 62,212 CONSOLIDATED STATEMENTS OF CASH FLOWS As of December 31, In thousands of euros 2016 2017 Cash flows from operating activities Net profit (loss) (22,082) (24,112) Operating activities Amortization and depreciation 203 224 Retirement pension obligations 31 26 Expenses relating to share-based payments 4,635 4,800 Other financial items — 77 Operating cash flows before change in working capital (17,213) (18,984) Accounts receivable (3) 19 Accounts payable, net of prepayments (3,459) 384 Other receivables 973 (976) Other current liabilities 60 775 Change in working capital (2,429) 202 Net cash flowsfrom operating activities (19,642) (18,782) Cash flows from investment activities Acquisitions of property, plant, and equipment (188) (236) Acquisitions of intangible assets (1) — Acquisitions / reimbursement of non-current financial assets 8 (232) Acquisitions / reimbursement of current financial assets — (216) Sales of property, plant, and equipment 11 — Net cash flows from investment activities (170) (684) Cash flows from financing activities Conditional advances received 2,300 — Treasury shares (145) (84) Warrants issuance 140 257 Capital increases, net of transaction costs 41,439 20,774 Net cash flows from financing activities 43,735 20,946 Increase/(decrease) in cash and cash equivalents 23,922 1,480 Cash and cash equivalents at the beginning of the period 30,060 53,982 Effect of changes in exchange rates on cash and cash equivalent — (14) Cash and cash equivalents at the close of the period 53,982 55,448 GENSIGHT BIOLOGICS – 2017 Registration Document– 15